Hospitals | April 08, 2026
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
The inspection is now closed, and no regulatory action has been recommended
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
Huwel’s diagnostic solutions leverage open RT-PCR system
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
Subscribe To Our Newsletter & Stay Updated
